Compare STTK & VINP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STTK | VINP |
|---|---|---|
| Founded | 2016 | 2009 |
| Country | United States | Brazil |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 683.8M | 638.8M |
| IPO Year | 2020 | 2020 |
| Metric | STTK | VINP |
|---|---|---|
| Price | $7.30 | $9.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | $10.00 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 1.3M | 29.2K |
| Earning Date | 05-01-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 5.72% |
| EPS Growth | ★ 53.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,000,000.00 | N/A |
| Revenue This Year | N/A | $18.07 |
| Revenue Next Year | N/A | $12.74 |
| P/E Ratio | ★ N/A | $24.41 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.80 | $9.22 |
| 52 Week High | $8.33 | $13.61 |
| Indicator | STTK | VINP |
|---|---|---|
| Relative Strength Index (RSI) | 54.26 | 36.78 |
| Support Level | $5.87 | N/A |
| Resistance Level | $7.75 | $10.28 |
| Average True Range (ATR) | 0.52 | 0.25 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 55.08 | 17.17 |
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
Vinci Compass Investments Ltd is an alternative investment platform in Brazil offering asset management, wealth management, and financial advisory services. The company comprises of six business lines i) Global IP&S, (ii) Credit (including public & private credit, opportunistic capital solutions, and agribusiness credit), (iii) Private Equity, (iv) Equities, (v) Real Assets (including real estate, infrastructure and forestry) and (vi) Corporate Advisory.